Program
perflutren
Also written as “NH002 (Perflutren Lipid Microspheres) Injectable Suspension”, “DEFINITY®” and “Perflutren Lipid Microsphere Injectable Suspension”.
Its studies are mostly in Heart Diseases · Coronary Artery Disease · Pulmonary Heart Disease · Cardiovascular Diseases · Ischemic Stroke, led by 3 companies.
Drug pagePerflutren: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lantheusits history only | 50 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | none ahead |
| Trust Bio-sonics | 32 open or running | phase 3since Jan 21, 2025 | Nov 6, 2019 | Feb 2027phase 3 · NCT06815627 |
| ImaRx Therapeuticsits history only | 10 open or running | phase 2since Jul 25, 2007 | Jul 25, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Trust Bio-sonics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2019First study: phase 2 study in Heart DiseasesFirst studyNCT04185246 · 36 enrolled · Taiwan
- Jan 21, 2025Phase 3 study in Heart DiseasesNCT06815627 · 150 enrolled · Taiwan
- Jul 28, 2026Phase 3 study in Heart DiseasesNCT07740421 · 150 planned
Ahead
- Feb 2027Primary completion: phase 3 study in Heart DiseasesNCT06815627
- Jul 2027Primary completion: phase 3 study in Heart DiseasesNCT07740421
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Trust Bio-sonics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07740421Heart Diseases | 3 | Not yet recruiting | Jul 2027 | 150 |
| NCT06815627Heart Diseases · Taiwan | 3 | Active, not recruiting | Feb 2027 | 150 |
| NCT04185246Heart Diseases · Taiwan | 2 | Completed | Jul 1, 2020 | 36 |
How it is read
Names in the registry
- “NH002 (Perflutren Lipid Microspheres) Injectable Suspension”, 3 entries
- “DEFINITY®”, 2 entries
- “Perflutren Lipid Microsphere Injectable Suspension”, 1 entry
- “DEFINITY”, 1 entry
- “Definity”, 1 entry
Conditions, from the studies’ own filings
- Heart Diseases, 5 studies
- Coronary Artery Disease, 1 study
- Pulmonary Heart Disease, 1 study
- Cardiovascular Diseases, 1 study
- Ischemic Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.